Skip to main content
SpringerLink
Log in

Opinion and Evidence in Neurology and Psychiatry

  • From the World Literature
  • Published:
CNS Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was supported by Solvay Pharmaceuticals.

  2. US physicians can prescribe buprenorphine for periods of ≤30 days; during the study the medication was largely administered on site.

  3. Some of the researchers were affiliated with Pfizer Inc., New York, USA, and Ingenium Clinical Research, Illinois, USA.

  4. These trials were both supported by Pfizer Inc.

  5. Data were adjusted for age, gender, race, marital status, concomitant use of other diabetogenic agents and measures of diabetes screening.

  6. The study was provided with financial support from Serono International SA, Switzerland, with which one of the researchers was affiliated.

  7. Costs (2000 values) were those related to standard care within the health systems of the UK and France, as described in a previous study.

  8. This study was supported by Astra Zeneca Germany.

  9. A mean of ≥2 BP measurements of ≥200mm Hg systolic and/or ≥110mm Hg diastolic 6-24 hours after admission or ≥ 180mm Hg systolic and/or ≥105mm Hg diastolic 24-36 hours after admission.

  10. The study was supported by Pfizer Global Research and Development, with which three of the researchers were affiliated. One of the researchers was affiliated with Innovus Research, Inc., Canada.

  11. Costs (2002 values) were those associated with study drugs and rescue medication, and were assessed from a healthcare system perspective.

References

  • Lamberg L. ADHD often undiagnosed in adults: appropriate treatment may benefit work, family, social life. JAMA 2003 Sep; 290(12): 1565–7

    Article  PubMed  CAS  Google Scholar 

Reference

  • Committee on Safety of Medicines. Safety of venlafaxine in children and adolescents under 18 years in the treatment of depressive illness. Internet document [2 pages]: 19 Sep 2003 [online]. Available from URL: http://www.mhra.gov.uk [Accessed 2003 Oct 28]

References

  1. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003 Sep 17; 290(11): 1467–73

    Article  PubMed  CAS  Google Scholar 

  2. Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA 2003 Sep 17; 290(11): 1517–9

    Article  PubMed  CAS  Google Scholar 

References

  1. Eli Lilly and Company. Lilly announces FDA notification of class labeling for atypical antipsychotics regarding hyperglycemia and diabetes. Media release: 17 Sep 2003 [online]. Available from URL: http://www.lilly.com [Accessed 2003 Oct 28]

  2. Pfizer Inc. Pfizer statement on FDA letter requesting label change for antipsychotics. Media release: 19 Sep 2003 [online]. Available from URL: http://www.pfizer.com [Accessed 2003 Oct 28]

References

  1. Fudala PJ, Bridge TP, Herbert S, et al. for the Buprenorphine/ Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003 Sep 4; 349(10): 949–58

    Article  PubMed  CAS  Google Scholar 

  2. Clark HW. Office-based practice and opioid-use disorders. N Engl J Med 2003 Sep 4; 349(10): 928–30

    Article  PubMed  CAS  Google Scholar 

References

  1. Wagner KD, Ambrosini P, Rynn M, et al., for the Sertraline Pediatric Depression Study Group. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003 Aug 27; 290(8): 1033–41

    Article  PubMed  CAS  Google Scholar 

  2. Varley CK. Psychopharmacological treatment of major depressive disorder in children and adolescents. JAMA 2003 Aug 27; 290(8): 1091–3

    Article  PubMed  Google Scholar 

Reference

  • Cunningham F, Lambert B, Miller DR, et al. Antipsychotic induced diabetes in veteran schizophrenic patients. Pharmacoepidemiol Drug Saf 2003 Aug; 12 Suppl. 1: 154–5

    Google Scholar 

Reference

  • Lepen C, Coyle P, Vollmer T, et al. Long-term cost effectiveness of interferon-beta-1a in the treatment of relapsing-remitting multiple sclerosis: an econometric model. Clin Drug Invest 2003; 23(9): 571–81

    Article  CAS  Google Scholar 

Reference

  • Schrader J, Lüders S, Kulschewski A, et al., for the ACCESS Study Group. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003 Jul; 34(7): 1699–1703

    Article  PubMed  Google Scholar 

Reference

  • Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003 Jul; 160: 1209–22

    Article  PubMed  Google Scholar 

Reference

  • Wells N, Hettiarachchi J, Drammond M, et al. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health 2003 Jul; 6(4): 438–47

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opinion and Evidence in Neurology and Psychiatry. CNS Drugs 17, 1059–1065 (2003). https://doi.org/10.2165/00023210-200317140-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200317140-00005

Search

Navigation